Boule Diagnostics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Torben Nielsen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Torben Nielsen

no data

Permanencia

Mr. Torben Nielsen is Chief Executive Officer and Group President of Boule Diagnostics AB (publ). Mr. Nielsen joined the Boule Diagnostics AB (publ) in April 2024.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Torben Nielsen	CEO & Group President	no data	sin datos	sin datos
Holger Lembrer	Chief Financial Officer	less than a year	sin datos	sin datos
Eduardo Pagani	Chief Operating Officer	no data	sin datos	sin datos
Jorgen Jehander	Head of Development Department & Interim CTO	1.3yrs	sin datos	sin datos
Simonetta Tumbiolo	Senior Vice President of Marketing	less than a year	sin datos	sin datos
Aishat Bislieva	Senior Vice President of People & Culture	1.6yrs	sin datos	sin datos
Kiarash Farr	Senior Vice President of Commercial Operations	6.2yrs	sin datos	0.010% SEK 3.4k
David Metrena	Senior Vice President of Commercial Operations of US	1.9yrs	sin datos	sin datos

1.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 8BD no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yvonne Martensson	Independent Director	3yrs	kr500.00k	0.038% SEK 12.5k
Thomas Eklund	Director	10.3yrs	kr300.00k	10.4% SEK 3.4m
Karin Dahllof	Independent Director	9.3yrs	kr250.00k	0.057% SEK 18.8k
Rikke Rytter	Director	no data	sin datos	sin datos
Emil Hjalmarsson	Director	2.3yrs	kr125.00k	0.067% SEK 21.9k
Torben Jorgensen	Independent Chairman of the Board	3.3yrs	kr250.00k	0.051% SEK 16.9k

3.2yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 8BD se considera experimentada (3.3 años de antigüedad promedio).

Boule Diagnostics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Boule Diagnostics AB (Publ) Appoints Rikke Rytter as Director

President recently bought €88k worth of stock

Boule Diagnostics AB (publ), Annual General Meeting, May 04, 2023

President recently bought €12k worth of stock

Independent Chairman of the Board recently bought €113k worth of stock

President recently bought €9.8k worth of stock

Recent updates

Boule Diagnostics AB (Publ) Appoints Rikke Rytter as Director

First quarter 2024 earnings released: EPS: kr0.25 (vs kr0.20 in 1Q 2023)

Full year 2023 earnings released: EPS: kr0.64 (vs kr0.46 in FY 2022)

Boule Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

New minor risk - Share price stability

Full year 2023 earnings released: EPS: kr0.64 (vs kr0.46 in FY 2022)

Boule Diagnostics AB (publ) to Report Q2, 2024 Results on Jul 22, 2024

Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.15 in 2Q 2022)

Boule Diagnostics AB (publ) to Report Q1, 2024 Results on May 07, 2024

Full year 2022 earnings released: EPS: kr0.46 (vs kr1.20 in FY 2021)

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Sep 09, 2023

President recently bought €88k worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: kr0.15 (vs kr0.07 loss in 2Q 2021)

Boule Diagnostics AB (publ), Annual General Meeting, May 04, 2023

Boule Diagnostics AB (publ) to Report Q1, 2023 Results on May 03, 2023

First quarter 2022 earnings released: EPS: kr0.24 (vs kr0.02 in 1Q 2021)

Upcoming dividend of kr0.55 per share

Full year 2021 earnings released: EPS: kr1.20 (vs kr2.47 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS kr0.37 (vs kr1.04 in 3Q 2020)

President recently bought €12k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr2.21 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Independent Chairman of the Board recently bought €113k worth of stock

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Revenue misses expectations

Boule Diagnostics AB (publ) to Report Fiscal Year 2020 Results on Feb 03, 2021

New 90-day high: €5.65

Third quarter 2020 earnings released: EPS kr1.04

Revenue misses expectations

New 90-day low: €4.82

President recently bought €9.8k worth of stock

New 90-day low: €5.09

President recently bought €16k worth of stock

Boule Diagnostics AB (publ) to Report Q1, 2021 Results on May 06, 2021

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad